Form 4: KalVista Pharmaceuticals Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Edward P. Feener, Chief Scientific Officer of KalVista Pharmaceuticals, sold shares to cover tax withholding obligations related to vesting of restricted stock units and performance stock units.
Summary
- Edward P. Feener, the Chief Scientific Officer of KalVista Pharmaceuticals, executed transactions involving the company's common stock.
- On May 17, 2024, Feener acquired 18,789 shares through the vesting of restricted stock units (RSUs) and performance stock units (PSUs).
- On May 20, 2024, Feener sold 8,088 shares at a weighted average price of $11.7645 per share, with prices ranging from $11.7644 to $11.965.
- The sale was to cover tax withholding obligations associated with the vesting of RSUs and PSUs and was not a discretionary transaction.
- Following these transactions, Feener directly owns 72,858 shares of KalVista Pharmaceuticals' common stock.
- Feener also holds 14,190 and 14,583 restricted stock units and 14,583 performance stock units.
Sentiment
Score: 6
Explanation: Neutral sentiment. The transactions are routine and related to tax obligations, not necessarily indicative of a change in the executive's confidence in the company.
Positives
- The vesting of RSUs and PSUs indicates that Feener is meeting certain performance or service requirements, which could be viewed positively.
Negatives
- The sale of shares, even for tax purposes, could be interpreted negatively by some investors, although it is a common practice.
Risks
- While the sale was to cover tax obligations, any significant insider selling can create short-term price volatility.
Industry Context
Insider transactions are common in the pharmaceutical industry, especially around vesting events. Investors often monitor these filings to gauge executive sentiment, but sales to cover taxes are generally viewed as routine.
Comparison to Industry Standards
- Comparing Feener's transactions to similar insider filings at companies like BioCryst Pharmaceuticals or Ionis Pharmaceuticals shows that 'sell to cover' transactions are a standard practice.
- The size of the transaction is relatively small compared to the overall market capitalization of KalVista Pharmaceuticals, suggesting it is unlikely to have a significant long-term impact.
Stakeholder Impact
- The sale of shares could have a minor short-term impact on shareholders due to potential price fluctuations.
Key Dates
| Date | Description |
|---|---|
| 08/17/2022 | Vesting Commencement Date for 1/16th of RSUs, vesting quarterly. |
| 11/17/2022 | Vesting Commencement Date for 1/12th of RSUs, vesting quarterly. |
| 06/08/2023 | Date of grant of PSUs to the Reporting Person. |
| 08/17/2023 | Vesting Commencement Date for 1/4th of PSUs, vesting quarterly upon achievement of Performance Metrics. |
| 01/10/2024 | Date of grant of PSUs to the Reporting Person. |
| 02/17/2024 | Vesting Commencement Date for 1/4th of PSUs, vesting quarterly upon achievement of Performance Metrics. |
| 05/17/2024 | Date of RSU and PSU vesting and acquisition of 18,789 shares. |
| 05/20/2024 | Date of sale of 8,088 shares. |
| 05/21/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.